ImmunityBio, Inc. (IBRX) vs Madrigal Pharmaceuticals, Inc. (MDGL)
- ImmunityBio, Inc. IBRX 9.18 −8.20%
- Madrigal Pharmaceuticals, Inc. MDGL 449.74 −2.19%
ImmunityBio, Inc. and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. ImmunityBio, Inc. and Madrigal Pharmaceuticals, Inc. are of similar size ($10.6B and $10.6B). ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 149.0%. Madrigal Pharmaceuticals, Inc. has the higher net margin (−25.3% vs −598.6%) and the lower return on invested capital (−787.3% vs 0.00%). Across the 16 metrics below, Madrigal Pharmaceuticals, Inc. leads on 9 and ImmunityBio, Inc. on 7.
Valuation
Profitability
| Metric | IBRX | MDGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.34% | 91.48% | 65.16% |
| Operating margin | (151.88%) | (25.13%) | 0.00% |
| Net margin | (598.56%) | (25.32%) | 0.00% |
| Free cash flow margin | (173.76%) | (16.07%) | 0.00% |
| Return on equity | 122.85% | (53.31%) | (56.36%) |
| Return on assets | (192.58%) | (28.77%) | (48.04%) |
| Return on invested capital | 0.00% | (787.33%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack